development and implementation of successful and innovative regulatory strategies. In addition, we
have worked with hundreds of companies to remediate, maintain and improve their regulatory compliance.
We are experienced, privately held and totally independent.
Our project managers and consultants understand your business objectives
and commit to achieving them with you.
“EMA Q&A Guidance Provides Clarity on Adaptive Licensing Pilot Program”
Matthew Weinberg, CEO, spoke to FDANews about EMA’s adaptive licensing pilot program.
“How Outsourcing Can Accelerate the Drug Development Process”
Our CEO wrote for Drug Discovery & Development about how companies that outsource their entire regulatory affairs function can accelerate the drug development process.
“Commentary: New trend in regulatory affairs consulting delivers reduced costs and improved processes”
Matthew Weinberg, CEO, writes for the August issue of DDNews about a new trend in the regulatory affairs world, regulatory outsourcing. In order to deal with increased workloads, many companies are now outsourcing their entire regulatory function.
Éclat Receives FDA Approval for VAZCULEP™
Congratulations to our client, Éclat, on the recent FDA approval of the company’s New Drug Application (NDA) for VAZCULEP™ (phenylephrine hydrochloride injection)! Read the full press release here.
September 18, 2014, New Brunswick, NJ: The Weinberg Group will be exhibiting at the 13th Annual Contract Pharma Contracting and Outsourcing Conference. To set up a time to meet with us, please send us an email.